NCT04233502View on ClinicalTrials.gov

Efficacy and Safety of Slenyto for Insomnia in Children With ASD

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2022

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Melatonin

prolonged release 1 mg and 5 mg mini-tablets coated odorless and tasteless to facilitate swallowing

DRUG

Placebo

Placebo melatonin

Sponsors
All Listed Sponsors
lead

Neurim Pharmaceuticals Ltd.

INDUSTRY

NCT04233502 - Efficacy and Safety of Slenyto for Insomnia in Children With ASD | Biotech Hunter | Biotech Hunter